Full-Time

Senior Corporate Paralegal

Posted on 10/6/2025

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

Compensation Overview

$93k - $115k/yr

+ Bonus

Bridgewater Township, NJ, USA + 2 more

More locations: Philadelphia, PA, USA | Malvern, PA, USA

In Person

Category
Legal & Compliance (2)
,
Requirements
  • Associate required; Bachelor’s Degree in Paralegal Studies or similar discipline preferred.
  • 5+ years' experience as a corporate paralegal with specific experience or knowledge in the formation and management of corporate entities and related record keeping
  • 5+ years’ experience with managing and completing Section 16 filings and other SEC filings
  • 2+ years’ experience in loading, maintaining and administering a subsidiary management database
  • Proficient in forming business entities, including drafting articles of incorporation, bylaws, organizational documents, stock certificates, and managing state and foreign corporation filings
  • Strong knowledge of corporate structure, including ownership, officers, directors, and subsidiaries
  • Skilled in coordinating internal processes and responding to outside counsel requests
  • Experienced in preparing and maintaining corporate records and related correspondence
  • Familiar with corporate law and state filing requirements, including interactions with Secretaries of State offices
  • Able to collaborate with the Tax Department on state registrations, withdrawals, annual reports, franchise tax filings, and tax clearance matters
  • Proficiency in Diligent database (or similar)
  • Ability to work in a team environment.
  • Strong organizational, leadership, and interpersonal skills
  • Able to work independently or collaboratively across teams and regions
  • Skilled at prioritizing, meeting deadlines, and performing under pressure
  • Maintains confidentiality and attention to detail
  • Flexible work hours to meet project needs
  • Proficient in Microsoft Office Suite and collaboration tools (Teams, Zoom)
Responsibilities
  • Managing Section 16 filings.
  • Drafting minutes of Board meetings, Board committee meetings, Management committees.
  • Maintaining, supervising and administering subsidiary management database (Diligent).
  • Intensive interaction with domestic service companies to ensure that documentation is drafted, executed and timely filed, including annual report filings, qualification and withdrawal documentation, name change documentation, as well as interaction with various Secretaries of State.
  • Preparing and managing D&O questionnaires.
  • Coordinating annual and extraordinary shareholder meetings.
  • Coordinating due diligence for major projects (e.g., financings, acquisitions, and divestitures).
  • Regular interaction with international service companies and outside law firms to ensure that documentation is properly executed and filed, including review of minutes and corporate filings.
  • Responding to inquiries from Mallinckrodt and outside personnel regarding the above matters.
  • Supporting KYC inquiries.
  • Supporting other business functions.
  • Proactively monitoring lists of directors and officers.
  • Other duties and special projects as assigned.
Desired Qualifications
  • Bachelor’s Degree in Paralegal Studies or similar discipline preferred.

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Company News

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

INACTIVE